| Autor: |
Sabrina Arena, Alberto Bardelli, Federica Di Nicolantonio, Serena Nik-Zainal, Andrea Sartore-Bianchi, Salvatore Siena, Silvia Marsoni, Michael Linnebacher, Pietro Andrei, Gianluca Mauri, Carlotta Cancelliere, Andrea Degasperi, Giorgio Corti, Simona Lamba, Federica Pisati, Gaia Grasso, João M. L. Dias, Annalisa Lorenzato, Rosaria Chilà, Elisa Mariella, Kristi Buzo, Nicole M. Reilly, Erika Durinikova |
| Rok vydání: |
2023 |
| DOI: |
10.1158/1078-0432.c.6532661.v1 |
| Popis: |
Purpose:Genomic instability is a hallmark of cancer and targeting DNA damage response (DDR) is emerging as a promising therapeutic strategy in different solid tumors. The effectiveness of targeting DDR in colorectal cancer has not been extensively explored.Experimental Design:We challenged 112 cell models recapitulating the genomic landscape of metastatic colorectal cancer with ATM, ATR, CHK1, WEE1, and DNA-PK inhibitors, in parallel with chemotherapeutic agents. We focused then on ATR inhibitors (ATRi) and, to identify putative biomarkers of response and resistance, we analyzed at multiple levels colorectal cancer models highly sensitive or resistant to these drugs.Results:We found that around 30% of colorectal cancers, including those carrying KRAS and BRAF mutations and unresponsive to targeted agents, are sensitive to at least one DDR inhibitor. By investigating potential biomarkers of response to ATRi, we found that ATRi-sensitive cells displayed reduced phospho-RPA32 foci at basal level, while ATRi-resistant cells showed increased RAD51 foci formation in response to replication stress. Lack of ATM and RAD51C expression was associated with ATRi sensitivity. Analysis of mutational signatures and HRDetect score identified a subgroup of ATRi-sensitive models. Organoids derived from patients with metastatic colorectal cancer recapitulated findings obtained in cell lines.Conclusions:In conclusion, a subset of colorectal cancers refractory to current therapies could benefit from inhibitors of DDR pathways and replication stress. A composite biomarker involving phospho-RPA32 and RAD51 foci, lack of ATM and RAD51C expression, as well as analysis of mutational signatures could be used to identify colorectal cancers likely to respond to ATRi. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
